Budget impact analysis of dabigatran compared with rivaroxaban in the prevention of the thromboembolic risk in patients with non-valvular atrial fibrillation. FE [Internet]. 2017 Nov. 14 [cited 2025 Oct. 29];18(1). Available from: https://journals.seedstm.com/index.php/FE/article/view/1327